Geriatric Nursing
Volume 27, Issue 5 , Pages 265-270 , September 2006

Management of Urinary Incontinence in Older Persons

References 

  1. Harrington C, Carrillo H, Mercado-Scott C. Nursing facilities, staffing, residents, and facility deficiencies, 1998 through 2004 (Urinary Incontinence and Bladder Training). Rockville, MD: Agency for Health Care Policy & Research; 2005;(#H500-97-0002, 52–3)
  2. Durrant J, Snape J. Urinary incontinence in nursing homes for older people. Age Ageing. 2003;32:12–18
  3. Nelson R, Furner S, Jesudason V. Urinary incontinence in Wisconsin skilled nursing facilities: Prevalence and associations in common with fecal incontinence. J Aging Health. 2001;13:539–547
  4. McDonagh MS, Selover D, Santa J, et al. Drug class review on agents for overactive bladder (Final Report. Oregon Health & Science University). 2005;December. Available www.ohsu.edu/drugeffectiveness/reports/final.cfm. Cited on June 8, 2006
  5. Fonda D, DuBeau C, HarareD , et al. Incontinence in the frail elderly. In:  Abrams P,  Cardozo L,  Khoury S editor. Incontinence. Vol. 2:Paris: Health Publications; 2005;p. 1165–1239
  6. National Nursing Home Quality Measures. User’s manual (v. 1.2). U.S. Department of Health & Human Services, Center for Medicare & Medicaid. 2004;November. Available www.cms.hhs.gov/NursingHomeQualityInits/.
  7. Ouslander JG, Osterweil D, Morley J. Incontinence. In: Medical Care in the Nursing Home. 2nd ed.. New York: McGraw-Hill Professional; 1996;p. 225–249
  8. Jumadilova Z, Zyczynski P, Paul B, Narayanan S. Urinary incontinence in the nursing home: resident characteristics and prevalence of drug treatment. Am J Manag Care. 2005;11:S112–S120
  9. Schmidt RA, Zermann DH, Doggweiler R. Urinary incontinence update: old traditions and new concepts. Adv Intern Med. 1999;44:19–57
  10. Goode PS, Burgio KL. Pharmacologic treatment of lower urinary tract dysfunction in geriatric patients. Am J Med Sci. 1997;314:262–267
  11. Burgio KL, Locher JL, Goode PS, et al. Behavioral and drug treatment for urge incontinence in older women: a randomized controlled trial. JAMA. 1998;280:1995–2000
  12. Debruyne FM, Witjes WP, Fitzpatrick J, et al. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol. 1996;30:369–376[Erratum, Eur Urol 1997;31:458.]
  13. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazoin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533–539
  14. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol. 1997;157:525–530
  15. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urol. 1998;51:892–900
  16. Lepor H, Williford WO, Barry MJ, et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol. 1998;160;:1358–1367
  17. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92:257–261
  18. Boyle P, Robertson C, Manski R, et al. Meta-analysis of randomized trials of terozosin the treatment of benign prostatic hyperplasia. Urol. 2001;58:717–722
  19. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urol. 2001;57:414–421
  20. Birns J, Lukkari E, Malone-Lee JG, et al. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int. 2000;85:793–798
  21. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gyn. 2000;95:718–721
  22. Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol. 1999;161:1809–1812
  23. Homma Y, Paick JS, Lee JG, et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. 2003;92:741–747
  24. Barkin J, Corcos J, Radomski S, et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge incontinence. Clin Ther. 2004;26:1026–1036
  25. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392–399
  26. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended-release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol. 2005;48:464–470
  27. Chu FM, Dmochowski RR, Lama DJ, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gyn. 2005;192:1849–1854
  28. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a U.S. consensus panel of experts. Arch Intern Med. 2003;163:2716–2724
  29. In: Urinary Incontinence: Anticholinergic Agents, Genitourinary Smooth Muscle Relaxants (Geriatric Pharmaceutical Care Guidelines). Covington, KY: Omnicare; 2006;p. 673–688
  30. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol. 2004;172:1021–1025
  31. Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Obstet Gyn. 2003;189:1106–1113
  32. Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study in men. BJU Int. 2002;89:855–862
  33. Rembratt A, Riis A, Morgaard JP. Desmopressin treatment in nocturia: an analysis of risk factors for hyponatremia. Neurourol Urodyn. 2006;25:105–109
  34. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. 2004;23:302–305
  35. Engberg S, Kincade J, Thompson D. Future directions for incontinence research with frail elders. Nursing Res. 2004;53:S22–S29

PII: S0197-4572(06)00229-1

doi: 10.1016/j.gerinurse.2006.08.004

Geriatric Nursing
Volume 27, Issue 5 , Pages 265-270 , September 2006

Article Tools

* Image Usage & Resolution